Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eururo.2009.09.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy Versus Intensity Modulated Radiation Therapy for Localized Prostate Cancer.
Int J Radiat Oncol Biol Phys
September 2024
Department Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address:
Purpose: Men with localized prostate cancer may receive either photon-based intensity modulated radiation therapy (IMRT) or proton beam therapy (PBT). The PARTIQoL trial (NCT01617161) demonstrates the feasibility of performing a large, multicenter phase 3 randomized trial comparing IMRT with PBT for localized prostate cancer. Here, we report baseline features of patients enrolled on this trial and present strategies to improve feasibility of other similar trials.
View Article and Find Full Text PDFArtificial intelligence-based personalized clinical decision-making for patients with localized prostate cancer: surgery versus radiotherapy.
Oncologist
December 2024
Department of Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China.
Background: Surgery and radiotherapy are primary nonconservative treatments for prostate cancer (PCa). However, personalizing treatment options between these treatment modalities is challenging due to unclear criteria. We developed an artificial intelligence (AI)-based model that can identify patients with localized PCa who would benefit more from either radiotherapy or surgery, thereby providing personalized clinical decision-making.
View Article and Find Full Text PDFNon-invasively identifying candidates of active surveillance for prostate cancer using magnetic resonance imaging radiomics.
Vis Comput Ind Biomed Art
July 2024
School of Engineering Medicine, Beihang University, Beijing, 100191, China.
Active surveillance (AS) is the primary strategy for managing patients with low or favorable-intermediate risk prostate cancer (PCa). Identifying patients who may benefit from AS relies on unpleasant prostate biopsies, which entail the risk of bleeding and infection. In the current study, we aimed to develop a radiomics model based on prostate magnetic resonance images to identify AS candidates non-invasively.
View Article and Find Full Text PDFPD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathway.
J Exp Med
July 2024
Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada.
While conventional wisdom initially postulated that PD-L1 serves as the inert ligand for PD-1, an emerging body of literature suggests that PD-L1 has cell-intrinsic functions in immune and cancer cells. In line with these studies, here we show that engagement of PD-L1 via cellular ligands or agonistic antibodies, including those used in the clinic, potently inhibits the type I interferon pathway in cancer cells. Hampered type I interferon responses in PD-L1-expressing cancer cells resulted in enhanced efficacy of oncolytic viruses in vitro and in vivo.
View Article and Find Full Text PDFAberrant activation of TGF-β/ROCK1 enhances stemness during prostatic stromal hyperplasia.
Cell Commun Signal
May 2024
Department of Urology, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Benign prostatic hyperplasia (BPH) is a multifactorial disease in which abnormal growth factor activation and embryonic reawakening are considered important factors. Here we demonstrated that the aberrant activation of transforming growth factor β (TGF-β)/Rho kinase 1 (ROCK1) increased the stemness of BPH tissue by recruiting mesenchymal stem cells (MSCs), indicating the important role of embryonic reawakening in BPH. When TGF-β/ROCK1 is abnormally activated, MSCs are recruited and differentiate into fibroblasts/myofibroblasts, leading to prostate stromal hyperplasia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!